Founded in 2019 in Edinburgh, Scotland. Lentitek has pioneered the development of an alternative approach to lentiviral vector production based on a novel promoter technology conceived by Dr Adam Inche. The unique Ltekplatform was conceived to address a number of key problems limiting adoption and progression of ATMP assets.
Leveraging private funding to unlock further grant finance Lentitek made rapid progress in demonstrating its technology through a successful proof of concept program. This early data coupled with the clear potential was recognised by the company winning the prestigious Scottish EDGE industrial biotechnology innovation top prize in 2022. Results from the PoC combined with continuous development of the platform through 2022-23 have driven further private investment and the company is now actively seeking application partners to exploit the technology.
A scientist by trade, Adam has a PhD in cancer biology from Oxford University and a executive MBA from Edinburgh. After a decade in R&D at AstraZeneca, Applied Biosystems & Lab901, Adam has spent the last 15 years in marketing & commercial roles developing market and product strategy for the likes of Agilent, Merck-BioReliance & Symbiosis.
With over 50 research publications and more than £7million in grant funding, John has built enormous academic and practical expertise in lentivirus vector design and production for clinical applications. John established and directs the molecular interventions research group in the UCL Division of Surgery, a team developing gene therapy technologies for diseases with a severe unmet need.
A senior leader in technology and life science industries with a broad range of experience across both start up, SMEs and large multinational technology companies. Currently CTO at Reactec Ltd, a safety tech IoT business and an active angel investor, Leif has helped both establish Lentitek and guide it throughout its journey.
Andy is an investor and advisor in new science and technology ventures, with 30 years’ experience in IT, business development, strategy and partnerships. Since selling his last venture in 2015, Andy has been an active member of the Scottish entrepreneurial ecosystem and supports a number of high-growth companies at from Pre-seed to Series A stages.
John is an experienced business advisor with a demonstrated history of working with high growth business clients in various key industries across Scotland. He is part of the investment portfolio management team at Scottish Enterprise, helping support various equity investments across multiple sectors.
Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA, United Kingdom
Copyright © 2024 Lentitek Ltd - All Rights Reserved.